Seamless Phase I–II Cancer Clinical Trials Using Kernel-Based Covariate Similarity

Kana Makino, Natsumi Makigusa, Masahiro Kojima · 2025

Read Seamless Phase I–II Cancer Clinical Trials Using Kernel-Based Covariate Similarity by Kana Makino, Natsumi Makigusa, Masahiro Kojima (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2511-01290.txt.

Introduction

Kana Makino, Natsumi Makigusa, and Masahiro Kojima design seamless early phase cancer trials that reuse phase one data wisely. United States regulators now push dose optimization earlier in oncology development. Designs that flow straight from phase one to phase two are gaining ground, provided the earlier data are borrowed with care.

Their nonparametric method discounts phase one observations according to how similar the patient covariate distributions are between the phases. Similarity is measured with a kernel based maximum mean discrepancy and turned into a dose specific weight inside a power prior for judging efficacy in phase two. They derive a confidence interval for the weight analytically, avoiding resampling. Simulations show better detection of truly effective doses without false alarms at weak ones, and a pancreatic cancer trial illustrates the method.

Catalog record

CREATORKana Makino, Natsumi Makigusa, Masahiro Kojima
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2511-01290

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Seamless Phase I–II Cancer Clinical Trials Using Kernel-Based Covariate Similarity Kana Makino, Natsumi Makigusa, Masahiro Kojima Abstract In response to the U.S. Food and Drug Administration’s (FDA) Project Optimus, a paradigm shift is underway in the design of early-phase oncology trials. To accelerate drug development, seamless Phase I/II designs have gained increasing attention, along with growing interest in the efficient reuse of Phase I data. We propose a nonparametric information-borrowing method that adaptively discounts Phase I observations according to the similarity of covariate distributions between Phase I and Phase II. Similarity is quantified using a kernel-based maximum mean discrepancy (MMD) and transformed into a dose-specific weight incorporated into a power-prior framework for Phase II efficacy evaluation, such as for the objective response rate (ORR). Considering the small sample sizes typical of early-phase oncology studies, we analytically derive a confidence interval for the weight, enabling assessment of borrowing precision without resampling procedures. Simulation studies under four toxicity scenarios and five baseline-covariate settings showed that the proposed method improved the probability that the lower bound of the 95% credible interval for ORR exceeded a prespecified threshold at efficacious doses, while avoiding false threshold crossings at weakly efficacious doses. A case study based on a metastatic pancreatic ductal adenocarcinoma trial illustrates the resulting borrowing weights and posterior estimates. Keywords: Bayesian optimal interval design; Project Optimus; maximum mean discrepancy 1 Introduction In response to the U.S. Food and Drug Administration’s (FDA) Project Optimus [ 1 ] , a paradigm shift in early-phase trial design is underway in oncology clinical trials. In particular, the previous standard approach of identifying the maximum tolerated dose (MTD) in Phase I and directly using it as the recommended Phase II dose or the recommended Phase III dose—a practice especially common for cytotoxic agents—is being reconsidered. Instead, it is now required to evaluate the efficacy of multiple dose levels in Phase II. Moreover, compared with other therapeutic areas, oncology drug development is generally associated with higher development costs, underscoring the need to optimize trial designs to reduce the overall development burden [ 2 ] . Several Phase I/II designs have been proposed that incorporate both safety and efficacy information for dose-finding without randomization in Phase II. Notable examples include Eff-Tox [ 3 , 4 ] , BOIN12 [ 5 ] , BOIN-ET [ 6 ] , uTPI [ 7 ] , and UNITED [ 8 ] . In contrast, some designs implement randomization in Phase II but use patient data from Phase I solely for selecting doses to be carried forward, without incorporating them into the efficacy analysis of Phase II. Examples of such designs include the method by Hoering et al. [ 9 ] , DROID [ 10 ] , and U-BOIN [ 11 ] . In recent years, there has been growing interest in leveraging historical data to improve the efficiency of clinical trials. The power prior framework, originally introduced by Ibrahim and Chen (2000) [ 12 ] and further developed by Ibrahim et al. (2003) [ 13 ] , provides a Bayesian mechanism for incorporating historical information into current analyses. In this framework, the likelihood of the historical data is raised to a power parameter between 0 and 1, allowing for a flexible degree of information borrowing depending on the relevance of the historical data to the current trial. Since its introduction, the power prior has inspired a variety of extensions to address its limitations and adapt it to more complex settings. For example, commensurate priors [ 14 ] model the relationship between current and historical parameters hierarchically, allowing for partial information borrowing based on their similarity. Bayesian hierarchical models have also been employed to integrate multiple data sources or subgroups [ 15 , 16 , 17 ] . More recently, elastic priors [ 18 ] have been proposed to dynamically adjust the amount of borrowing based on the level of agreement between the historical and current data. Other works have combined the power prior with propensity score methods to adjust for population differences and improve robustness in real-world applications. For instance, the propensity score–integrated power prior (PSPP) approach [ 19 ] allows for borrowing from external or real-world data while accounting for covariate imbalance, and subsequent extensions have generalized this framework to augment both trial arms [ 20 ] or to incorporate multiple external datasets [ 21 ] . In parallel, seamless Phase I/II designs have been proposed in which data from Phase I patients are carried forward into randomized Phase II. Zhao et al. [ 22 ] proposed an approach in which patients treated at dose levels selected for Phase II are reused from Phase I, provided that they meet the Phase II eligibility criteria. To account for potential differences in baseline distributions across dose levels, they employed covariate-adaptive randomization (minimization) in Phase II to ensure balance across treatment groups. Similarly, Kitabayashi et al. [ 23 ] proposed a method for seamless Phase I/II designs that borrows Phase I data using the Multi-source Exchangeability Model, allowing information sharing across doses and stages. However, when Phase I is conducted as a first-in-human study, patients may have more advanced disease or worse general condition compared with those enrolled in Phase II, leading to reduced responsiveness to treatment. In such cases, naively incorporating Phase I data into Phase II analyses may reduce the probability of success in Phase II. This paper proposes an information-borrowing method for cases where the distributions of patient backgrounds differ between Phase I and Phase II. Given the typically small sample sizes in Phase I oncology trials, we avoid model-based borrowing and instead propose a kernel-based approach. To control the extent of borrowing, we define a kernel-based weight taking values in [0,1] and apply it to the power-prior framework, allowing flexible discounting of Phase I data based on similarity. Because small sample sizes may raise concerns about the precision of the estimated weights, we also derive an analytical expression for their confidence intervals, enabling evaluation of the uncertainty associated with the borrowing strength. Furthermore, we assess the performance of the proposed method through extensive simulation studies and demonstrate its practical utility via a case study that illustrates the estimated borrowing weights and corresponding posterior results. This paper is organized as follows. Section 2 introduces the proposed methodology. Section 3 describes the simulation settings and presents the simulation results. Section 4 provides a case study and its results. Section 5 discusses the findings and implications of the proposed method. 2 Method In the context of seamless Phase I/II cancer trial design, various Phase I designs proposed in the literature can be adopted; there is no requirement to employ a specific design. However, to reliably identify the optimal biological dose (OBD), it may be advantageous to use a design that considers both safety and efficacy in dose escalation and allows the use of backfill cohorts—such as the BF-BOIN-ET design. In this study, we adopt the BF-BOIN-ET design for the Phase I part and conduct a randomized comparison of two dose levels in the Phase II part. In the BF-BOIN-ET design, dose escalation and de-escalation take into account both safety and efficacy, with the aim of identifying not only the maximum tolerated dose (MTD) but also the

Read the complete text